ELISA provides a fast, quantifiable, and convenient approach to monitor the protein level changes for a target of interest.
Figure 1: Assessment of(A) phospho Thr181 Tau and (B) phospho Thr231 Tau protein levels in Tg4510, an inducible mouse model of Tauopathy. Insoluble protein fractions were prepared from hippocampal tissue of 6 months old tTA control (expressing a tetracycline-controlled transactivator (tTA) under control of the CaMKIIα promoter), rTg4510 (expressing human tau containing the P301L mutation under the control of the CaMKIIα promoter), and rTg4510 mice treated with doxycycline to stop mutant tau expression (doxycycline treatment was started from 9 weeks to 6 months of age). rTg4510 mice expressed higher phosphorylated Tau proteins as compared to control tTA group. Furthermore, doxycycline treatment significantly reduced phospho Thr181 Tau and phospho Thr231 Tau proteins in rTg4510. Data is represented as average ± SEM.
One way ANOVA with Tukey’s multiple comparisons tests:symbols above each bar represent statistical comparison against tTA vehicle group [ns, not significant; ****, p≤0.0001]. Bracket indicate comparison between rTg4510 vehicle and rTg4510 doxycycline groups [####, p≤0.0001].